TY - JOUR
T1 - Differentiation of cancer from atrial fibrillation in patients with acute multifocal stroke
AU - Ito, Shinji
AU - Ueda, Akihiro
AU - Murate, Kenichiro
AU - Hirota, Seiko
AU - Fukui, Takao
AU - Ishikawa, Tomomasa
AU - Shima, Sayuri
AU - Hikichi, Chika
AU - Mizutani, Yasuaki
AU - Kizawa, Madoka
AU - Asakura, Kunihiko
AU - Mutoh, Tatsuro
N1 - Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/9/15
Y1 - 2016/9/15
N2 - Objective Acute multifocal embolic infarction (AMEI) is conventionally caused by etiologies such as cardioembolism due to atrial fibrillation (Af), but can also be caused by serious underlying diseases such as cancer. We characterized cancer-related AMEI and identified useful indicators for cancer-associated strokes. Methods A retrospective analysis was performed on 35 patients with Af-related AMEI and 35 patients with cancer-related AMEI selected from 1235 consecutive patients with acute infarcts. All patients received diffusion-weighted magnetic resonance (MR) imaging. Cerebral MR angiography, carotid and cardiac ultrasonography, electrocardiogram-monitoring and whole body computed tomography were also performed on these patients. D-dimer levels were evaluated on admission, and were measured during the sub-acute phase in 19 of the patients with Af and 27 of the patients with cancer. Results Acute phase D-dimer levels were significantly higher in patients with cancer than in patients with Af alone. The cut-off D-dimer value to identify cancer-associated infarcts was 2.0 μg/mL. D-dimer levels during the sub-acute phase remained elevated in the cancer patients. Conclusions We may differentiate cancer-associated AMEI from Af using a D-dimer level ≥ 2.0 μg/mL, which does not decrease during the sub-acute phase.
AB - Objective Acute multifocal embolic infarction (AMEI) is conventionally caused by etiologies such as cardioembolism due to atrial fibrillation (Af), but can also be caused by serious underlying diseases such as cancer. We characterized cancer-related AMEI and identified useful indicators for cancer-associated strokes. Methods A retrospective analysis was performed on 35 patients with Af-related AMEI and 35 patients with cancer-related AMEI selected from 1235 consecutive patients with acute infarcts. All patients received diffusion-weighted magnetic resonance (MR) imaging. Cerebral MR angiography, carotid and cardiac ultrasonography, electrocardiogram-monitoring and whole body computed tomography were also performed on these patients. D-dimer levels were evaluated on admission, and were measured during the sub-acute phase in 19 of the patients with Af and 27 of the patients with cancer. Results Acute phase D-dimer levels were significantly higher in patients with cancer than in patients with Af alone. The cut-off D-dimer value to identify cancer-associated infarcts was 2.0 μg/mL. D-dimer levels during the sub-acute phase remained elevated in the cancer patients. Conclusions We may differentiate cancer-associated AMEI from Af using a D-dimer level ≥ 2.0 μg/mL, which does not decrease during the sub-acute phase.
UR - http://www.scopus.com/inward/record.url?scp=84979608829&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979608829&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2016.07.054
DO - 10.1016/j.jns.2016.07.054
M3 - Article
C2 - 27538662
AN - SCOPUS:84979608829
SN - 0022-510X
VL - 368
SP - 344
EP - 348
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
ER -